The FDA has approved a sublingual formulation of buprenorphine and naloxone hydrochloride dihydrate from Accord Healthcare, expanding access to this essential medication for opioid dependence. This generic entry is likely to introduce competitive pricing pressure in the market, potentially driving revenue growth for the manufacturer while enhancing drug affordability.